加载中
NASDAQHealthcareMedical - Pharmaceuticals
最新数据
US$77.96
+US$0.87 · +1.13%
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
前收盘价
US$77.96
+US$0.87 · +1.13%
盘后
US$78.50
+US$0.54 · +0.69%
10月7日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
日内区间
当前US$77.96
52周区间
当前US$77.96
盘中时间采用ET。市场数据可能有所延迟。
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
日内区间
当前US$77.96
52周区间
当前US$77.96
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 6.78亿 USD | 4.23亿 USD | 2.7亿 USD | 2.2亿 USD | 3854.4万 USD |
| 销货成本 | 3.07亿 USD | 6091万 USD | 5652.4万 USD | 2289.5万 USD | 910万 USD |
| 毛利 | 3.7亿 USD | 3.62亿 USD | 2.14亿 USD | 1.97亿 USD | 2944.4万 USD |
| 研究与开发 | 9685.3万 USD | 1.12亿 USD | 7609.7万 USD | 6549万 USD | 9929.7万 USD |
| 销售、一般及管理费用 | 1.96亿 USD | 1.68亿 USD | 1.29亿 USD | 9795.1万 USD | 8594.8万 USD |
| 营业费用 | 2.93亿 USD | 4.08亿 USD | 2.39亿 USD | 1.88亿 USD | 1.86亿 USD |
| 利息收入 | 1164.7万 USD | 946.4万 USD | 854.4万 USD | 125.3万 USD | 9.7万 USD |
| 折旧和摊销 | 155.4万 USD | 169.5万 USD | 234.1万 USD | 240.2万 USD | 235.5万 USD |
| 营业利润 | 7722.1万 USD | −4561.6万 USD | −2519.6万 USD | 977.3万 USD | −1.57亿 USD |
| 净利润 | 5900.5万 USD | −4319.3万 USD | 1408.4万 USD | 1.83亿 USD | −1.58亿 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$86.40
上涨空间 10.83%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.04亿0.00%2.3万亿 USD0.03%US$381.03-0.40%
iShares Russell 2000 ETFIWM9175.75万0.12%785.63亿 USD0.19%US$277.7-1.29%
Vanguard Morningstar Small-Cap ETFVB7534.7万0.04%1853亿 USD0.03%US$286.98-1.41%
Vanguard Morningstar Small-Cap Growth ETFVBK4338.65万0.09%447亿 USD0.05%US$342.24-1.50%
iShares Russell 2000 Growth ETFIWO3298.87万0.23%142.49亿 USD0.24%US$355.37-1.43%
Dimensional - US Small Cap ETFDFAS2468.87万0.07%336.6亿 USD0.31%US$77.92-1.38%
Vanguard Russell 2000 ETFVTWO1915.77万0.10%180亿 USD0.06%US$112.21-1.26%
Dimensional - US Core Equity 2 ETFDFAC1206.13万0.01%882.76亿 USD0.21%US$45.18-0.57%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWODimensional - US Core Equity 2 ETFDFACAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
